Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Acq. announced
CC transcript
Inv. presentation
Quarterly results
Ensysce Biosciences, Inc. (LACQ) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 8-K Quarterly results
06/02/2023 8-K Other Events  Interactive Data
05/17/2023 POS EX Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]:
05/17/2023 AW Form AW - Amendment Withdrawal Request:
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/15/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "SERIES [A-1] [A-2] COMMON STOCK PURCHASE WARRANT ENSYSCE BIOSCIENCES, INC. Warrant Shares: _______ Initial Exercise Date: May [_], 2023 THIS SERIES [A-1] [A-2] COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and on or prior to 5:00 p.m. on [____,___] 12 but not thereafter, to subscribe for and purchase from Ensysce Biosciences, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise defin...",
"PREFUNDED COMMON STOCK PURCHASE WARRANT ENSYSCE BIOSCIENCES, INC. Warrant Shares: ______ Initial Exercise Date: May [_],2023 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from Ensysce Biosciences, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise defined herein shall have the m...",
"PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT ENSYSCE BIOSCIENCES, INC. Warrant Shares: 126,061 Initial Exercise Date: May 12, 2023 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT certifies that, for value received, H.C. Wainwright & Co., LLC or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and on or prior to 5:00 p.m. on May 10, 2028 but not thereafter, to subscribe for and purchase from Ensysce Biosciences, Inc., a Delaware corporation , up to 126,061 shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. This Warrant is being issued pursuant to that certain Engagement A...",
"NOTICE OF EXERCISE TO: Ensysce Biosciences, Inc., The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant , and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any. Payment shall take the form of : [ ] in lawful money of the United States; or [ ] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2, to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2. Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below: __________________...",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of May 10, 2023, between Ensysce Biosciences, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser a...",
"Ensysce Biosciences Investor Relations Contact:"
05/12/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/12/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/12/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/12/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/12/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
05/10/2023 EFFECT Form EFFECT - Notice of Effectiveness:
05/09/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
05/08/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
03/31/2023 8-A12G/A Form 8-A12G/A - Registration of securities [Section 12(g)]: [Amend]
03/24/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
03/06/2023 4 GOWER BOB G (Director) has filed a Form 4 on Ensysce Biosciences, Inc.
Txns: Bought 90,287 shares @ $0.4883, valued at $44.1k
03/02/2023 4 GOWER BOB G (Director) has filed a Form 4 on Ensysce Biosciences, Inc.
Txns: Bought 109,300 shares @ $0.4883, valued at $53.4k
Bought 270,000 shares @ $0.4777, valued at $129k
03/01/2023 D Form D - Notice of Exempt Offering of Securities:
02/14/2023 SC 13G/A HG Vora Capital Management, LLC reports a 2.1% stake in Ensyce Biosciences, Inc.
02/14/2023 SC 13G/A CVI Investments, Inc. reports a 4.9% stake in Ensysce Biosciences, Inc.
02/13/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
02/08/2023 8-A12G/A Form 8-A12G/A - Registration of securities [Section 12(g)]: [Amend]
02/07/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...
Docs: "DGCL",
"COMMON STOCK PURCHASE WARRANT ENSYSCE BIOSCIENCES, INC. Warrant Shares: _______ Initial Exercise Date: February 6, 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and on or prior to 5:00 p.m. on August 7, 2028 but not thereafter, to subscribe for and purchase from Ensysce Biosciences, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise defined herein shall have the meanings ...",
"PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT ENSYSCE BIOSCIENCES, INC. Warrant Shares: _______ Initial Exercise Date: February 6, 2023 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and on or prior to 5:00 p.m. on February 2, 2028 but not thereafter, to subscribe for and purchase from Ensysce Biosciences, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. This Warrant is issued pursuant to that certain Engagement Agreement, by...",
"Letter re: Registration Statement on Form S-3",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of February 2, 2023, between Ensysce Biosciences, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act as to the Shares and an exemption from the registration requirements of Section 5 of the Securities Act contained in Section 4 thereof and/or Regulation D thereunder as to the Warrants, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION ...",
"Ensysce Biosciences Investor Relations Contact:",
"Investor Contact"
02/06/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
02/01/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/01/2023 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "Ensysce Biosciences Announces the Distribution of Series A Preferred Stock to Holders of its Common Stock SAN DIEGO, CA / ACCESSWIRE / February 1, 2023 / Ensysce Biosciences, Inc. , a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that its Board of Directors has declared a dividend of 0.001 of a share of newly-designated Series A Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company’ s common stock held of record as of 5:00 p.m. Eastern Time on February 13, 2023. The outstanding shares of Series A Preferred Stock will vote together with the outstanding shares of the Company’ s common stock, as a single class, exclusively with respect to a reverse stock split..."
02/01/2023 8-A12G Form 8-A12G - Registration of securities [Section 12(g)]:
01/18/2023 EFFECT Form EFFECT - Notice of Effectiveness:
01/13/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
01/03/2023 424B4 Form 424B4 - Prospectus [Rule 424(b)(4)]:
12/30/2022 EFFECT Form EFFECT - Notice of Effectiveness:
12/16/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
12/16/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy